STOCK TITAN

LCIN - $LCIN STOCK NEWS

Welcome to our dedicated page for LCIN news (Ticker: $LCIN), a resource for investors and traders seeking the latest updates and insights on LCIN stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LCIN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LCIN's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lannett Company, Inc. has entered into a Restructuring Support Agreement (RSA) with its Senior Secured Note Holders and Second Lien Term Lenders. The agreement will reduce the company's secured debt by $511 million through conversion into equity, strengthening its financial position. The company will continue operations without interruption and expects near-term product launches and progress on new product development. The financial restructuring is expected to be completed by June 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
LCIN

OTC:LCIN

LCIN Rankings

LCIN Stock Data

164.73k
8.39M
14.26%
38.91%
11.54%
Drug Manufacturers—Specialty & Generic
Healthcare
Link
United States
Trevose